Channels In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses
Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL
Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2
Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator‐Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study
A case of ROS1‐rearranged lung adenocarcinoma in a young man with multiple serosal effusions: Diagnostic pitfalls in pericardial fluid cytology
Real‐World Survival Over 25 Years in Extensive‐Stage Small‐Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors
EXPRESSION OF CONCERN: A Newly Identified 45‐kDa JAK2 Variant with an Altered Kinase Domain Structure Represents a Novel Mode of JAK2 Kinase Inhibitor Resistance
Regulation, Function, and Expression of Matrix Metalloproteinase-9 in Colon, Lung, and Breast Cancers In Silico and Experimental Methods From Iraqi Metastatic Patients
Acquired BRAF-AGK Fusion Following Osimertinib Plus Savolitinib in EGFR-Mutated MET-Amplified Non-Small-Cell Lung Cancer: Durable Response to Gefitinib and Trametinib in a Case Report
EXPRESSION OF CONCERN: DIMP53‐1: A Novel Small‐Molecule Dual Inhibitor of p53–MDM2/X Interactions with Multifunctional p53‐Dependent Anticancer Properties
First‐Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK‐Positive Non‐Small Cell Lung Cancer with Brain Metastases: A Real‐World Multicenter Study from Vietnam
Prognostic and Predict Value of Peripheral Blood Circulating Tumor Cells Programmed Death‐Ligand 1 Expression and F‐18‐Fluorodeoxyglucose Metabolic Parameters in Patients With Advanced Non‐Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Identification of Novel Small‐Molecule Inhibitors Targeting KDM5B and Evaluation of Their Antitumour Effects
Brain metastases in non-small cell lung cancer: Prevalence, high-risk factors, and overall survival prognosis
Analyzing the Influence of Surgical Sequence on Perioperative Circulating Tumor Cells in Patients with Resectable Non-Small Cell Lung Cancer
Prospective Multicenter Observational Study of Anlotinib in Advanced Non‐Small Cell Lung Cancer: Real‐World Evidence From China
Clinical Utility of Comprehensive Genomic Profiling for Advanced Non‐Small Cell Lung Cancer: A Single‐Center Retrospective Study
Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer
Development of an Artificial Intelligence Web Application for Predicting Chemotherapy‐Induced Neutropenia in Patients With Non‐Small Cell Lung Cancer: A Prospective Study
Safety and Clinical Outcomes of Kanglaite Injection in Combination with Toripalimab and Chemotherapy for Advanced Non-Small Cell Lung Cancer: A Real-World Retrospective Analysis
The hsa_circ_0070354/miR‐4322/RAB3B Axis Facilitates the Carcinogenesis and Development of Non‐Small Cell Lung Cancer (NSCLC)
Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study
The Association between Pretreatment anemia and Overall Survival in Advanced Non-small Cell lung Cancer: A Retrospective Cohort Study Using Propensity Score Matching
Radiotherapy and Cardiovascular Disease Survival Risk in Non‐Small Cell Lung Cancer: A Population‐Based Study From the Surveillance, Epidemiology, and End Results Database
Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer
